An observational study in Neurology, Aromatic Amino Acid Decarboxylase Deficiency and Pediatric Neurological Disorder, sponsored by Istituto Giannina Gaslini. Recruiting at 10 sites in Italy. Open to participants aged 0 Days to 3 Days. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Istituto Giannina Gaslini · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Aromatic L-amino acid decarboxylase deficiency (AADC-D) is a rare genetic disorder that affects the production of neurotransmitters in the brain and can cause severe neurological and developmental problems. Early diagnosis may allow affected children to be referred promptly for specialist care and evaluation for available treatments, including gene therapy.
The purpose of this study is to develop a newborn screening protocol for AADC-D in the neonatal population of Liguria, Italy, and to estimate the incidence of the disease in this population. The study will also establish reference values for 3-O-methyldopa (3-OMD), a biochemical marker used to identify newborns who may have AADC-D, and determine appropriate screening cut-off values.
Approximately 16,000 newborns born in participating hospitals in Liguria will be included in the study. After informed consent is obtained from their parents or legal caregivers, blood samples will be collected using dried blood spot cards as part of the existing regional newborn screening procedures.
The samples will be analyzed using tandem mass spectrometry to measure 3-OMD levels. Samples with positive screening results will be retested. If the result remains positive, genetic testing of the DDC gene will be performed to confirm the diagnosis.
The study will evaluate 3-OMD levels in the neonatal population, establish and periodically refine screening thresholds, and assess the preliminary performance of the screening method. The results are expected to support the development of a reliable newborn screening program for AADC-D in Liguria and facilitate the early identification of affected newborns.
Istituto Giannina Gaslini is the lead sponsor of 54 studies on the registry; 35 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population will consist of approximately 16,000 newborns born at participating birth centers in the Liguria region, Italy. Newborns whose parents or legal caregivers have read the study information sheet and provided written informed consent will be eligible for inclusion. Dried blood spot samples will be collected as part of the regional newborn screening program to measure 3-O-methyldopa (3-OMD) levels and identify newborns who may have aromatic L-amino acid decarboxylase deficiency (AADC-D). Positive screening results will undergo repeat testing and, if confirmed, genetic testing of the DDC gene.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Development of an Analytical and Post-Analytical Newborn Screening Protocol for Aromatic L-Amino Acid Decarboxylase Deficiency (AADC-D)
Establishment of an analytical and post-analytical protocol for newborn screening of AADC-D using 3-O-methyldopa (3-OMD) measurement in dried blood spot samples by tandem mass spectrometry.
Time frame: Two years
Incidence of Aromatic L-Amino Acid Decarboxylase Deficiency (AADC-D) in the Neonatal Population of Liguria, Italy
Estimation of the incidence of AADC-D based on the number of newborns with genetically confirmed AADC-D identified through screening, relative to the total number of newborns screened.
Time frame: Two years.
Establishment of Neonatal 3-O-Methyldopa (3-OMD) Reference Values and Screening Cut-off Values
Determination of reference values for 3-OMD in the neonatal population and optimization of screening cut-off values to reduce the recall rate to below 1%
Time frame: 2 years
Development of Second-Tier and Confirmatory Biochemical Testing Methods for AADC-D
Development of second-tier analytical methods to improve the positive predictive value of newborn screening and biochemical confirmatory methods using liquid chromatography-tandem mass spectrometry (LC-MS/MS) on plasma and urine samples.
Time frame: 2 years
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2023 to primary completion in Dec 2025, 28 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aromatic amino acid decarboxylase deficiency
Istituto Giannina Gaslini